Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer

Specific PHGKB|Cancer|PHGKB

Breast Cancer Genomics

- Cancer PHGKB -

What's New

Last Posted: May 18, 2017

---

• Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.  
  Maxwell Kara N et al. Breast cancer research and treatment 2017 May
• Differential analysis of mutations in the Jewish population and their implications for diseases.  
  Einhorn Yaron et al. Genetics research 2017 May 99e3
• Heightened perception of breast cancer risk in young women at risk of familial breast cancer.  
  Glassey Rachael et al. Familial cancer 2017 May
• Multigene assays: Implications for breast cancer staging.  
  Greene Frederick L et al. Journal of surgical oncology 2017 May
• Multigene expression profile testing in breast cancer: is there a role for family physicians?  
  O'Brien M A et al. Current oncology (Toronto, Ont.) 2017 Apr 24(2) 95-102
• Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.  
  Frey Melissa K et al. Gynecologic oncology 2017 May
• Multigene testing for breast cancer risk assessment: an illusion of added clinical value.  
  Sokolenko Anna et al. Chinese clinical oncology 2017 Apr 6(2) 15
• Next generation sequencing is informing phenotype: a TP53 example.  
  O'Shea R et al. Familial cancer 2017 May
• Pathology update to the Manchester Scoring System based on testing in over 4000 families.  
  Evans D Gareth et al. Journal of medical genetics 2017 May
• Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.  
  Hyams David M et al. Journal of surgical oncology 2017 Feb